Electrophysiological Markers of Chemotherapy-Induced Polyneuropathy
- Authors: Tikhonova O.A.1, Druzhinina E.S.2, Druzhinin D.S.3
-
Affiliations:
- Immanuel Kant Baltic Federal University
- Pirogov Russian National Research Medical University
- Yaroslavl State Medical University
- Issue: Vol 19, No 2 (2025)
- Pages: 34-40
- Section: Original articles
- URL: https://journal-vniispk.ru/2075-5473/article/view/310261
- DOI: https://doi.org/10.17816/ACEN.1283
- EDN: https://elibrary.ru/HUVVST
- ID: 310261
Cite item
Abstract
Introduction. Electrophysiological testing is the gold standard for diagnosing polyneuropathy. However, its use in oncology practice for patients with chemotherapy-induced polyneuropathy (CIPN) remains limited and the value of its findings is not fully understood.
The study was aimed at identifying electrophysiological CIPN markers and evaluting their sensitivity and specificity.
Materials and methods. The study included patients (n = 71) over 18 years of age with solid tumor presenting with polyneuritic complaints following neurotoxic therapy with platinum-based agents and taxanes. Patients with known risk factors for polyneuropathy were excluded. Electrophysiological and clinical patient data were evaluated no earlier than 3 months following chemotherapy initiation.
Results. The study identified electromyographic markers: SRAR index (sural/radial ratio — the ratio between the action potential amplitudes of the sural and radial nerves) and the sural nerve action potential (SNAP), demonstrating equal sensitivity (73.7%) and high specificity (75% and 84.6%, respectively).
Conclusion. Electromyographic parameters such as SRAR and SNAP sural nerve can be utilized for the diagnosis and monitoring of CIPN in daily practice.
Full Text
##article.viewOnOriginalSite##About the authors
Olga A. Tikhonova
Immanuel Kant Baltic Federal University
Author for correspondence.
Email: offelia78@mail.ru
ORCID iD: 0000-0002-1796-0193
neurologist, assistant, Department of psychiatry and neurosciences
Russian Federation, 14 A. Nevskiy str., 236041Evgeniia S. Druzhinina
Pirogov Russian National Research Medical University
Email: offelia78@mail.ru
ORCID iD: 0000-0002-1004-992X
Cand. Sci. (Med.), Associate Professor, Department of neurology, neurosurgery and medical genetics named after academician L.O. Badalyan, Faculty of pediatrics
Russian Federation, MoscowDmitry S. Druzhinin
Yaroslavl State Medical University
Email: offelia78@mail.ru
ORCID iD: 0000-0002-6244-0867
Dr. Sci. (Med.), Associate Professor, Department of nervous diseases with medical genetics and neurosurgery
Russian Federation, YaroslavlReferences
- Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461–2470. doi: 10.1016/j.pain.2014.09.020
- Fuglsang-Frederiksen A, Pugdahl K. Current status on electrodiagnostic standards and guidelines in neuromuscular disorders. Clin Neurophysiol. 2011;122(3):440–455. doi: 10.1016/j.clinph.2010.06.025
- Novello BJ, Pobre T. Electrodiagnostic evaluation of peripheral neuropathy. Treasure Island; 2025.
- Griffith KA, Dorsey SG, Renn CL, et al. Correspondence between neurophysiological and clinical measurements of chemotherapy‐induced peripheral neuropathy: secondary analysis of data from the CI‐PERINOMS study. J Peripher Nerv Syst. 2014;19(2):127–135. doi: 10.1111/jns5.12064
- Cho KH, Han EY, Shin JC, et al. Comparison of clinical symptoms and neurophysiological findings in patients with chemotherapy induced peripheral neuropathy. Front Neurol. 2022;13:838302. doi: 10.3389/fneur.2022.838302
- Wang M, Bandla A, Sundar R, Molassiotis A. The phenotype and value of nerve conduction studies in measuring chemotherapy-induced peripheral neuropathy: a secondary analysis of pooled data. Eur J Oncol Nurs. 2022; 60:102196. doi: 10.1016/j.ejon.2022.102196
- Супонева Н.А., Арестова А.С., Мельник Е.А. и др. Валидация шкалы суммарной оценки мышечной силы (MRC sum score) для использования у русскоязычных пациентов с хронической воспалительной демиелинизирующей полинейропатией. Нервно-мышечные болезни. 2023;13(1):68–74. Suponeva NA, Arestova AS, Melnik EA, et al. Validation of the Medical Research Council sum score (MRCss) for use in Russian-speaking patients with chronic inflammatory demyelinating polyneuropathy. Neuromuscular Diseases. 2023;13(1):68–74. doi: 10.17650/2222-8721-2023-13-1-68-74
- Mooi CS, Lee KW, Yusof Khan AHK, et al. Using biothesiometer, Neuropathy Symptom Score, and Neuropathy Disability Score for the early detection of peripheral neuropathy: a cross-sectional study. Qatar Med J. 2024;2024(3):24. doi: 10.5339/qmj.2024.24
- Using the Common Terminology Criteria for Adverse Events (CTCAE — Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed). 2021;112(1):90–92. doi: 10.1016/j.ad.2019.05.009
- Stålberg E, Van Dijk H, Falck B, et al. Standards for quantification of EMG and neurography. Clin Neurophysiol. 2019;130(9):1688–1729. doi: 10.1016/j.clinph.2019.05.008
- Electromyography and neuromuscular disorders: clinical-electrodiagnostic-ultrasound correlations, Fourth Edition. J Clin Neurophysiol. 2021;38(4):e19. doi: 10.1097/WNP.0000000000000842
- Esper GJ, Nardin RA, Benatar M, et al. Sural and radial sensory responses in healthy adults: diagnostic implications for polyneuropathy. Muscle Nerve. 2005;31(5):628–632. doi: 10.1002/mus.20313
- Overbeek BUH, Van Alfen N, Bor JA, Zwarts MJ. Sural/radial nerve amplitude ratio: reference values in healthy subjects. Muscle Nerve. 2005;32(5):613–618. doi: 10.1002/mus.20421
- Rutkove SB, Kothari MJ, Raynor EM, et al. Sural/radial amplitude ratio in the diagnosis of mild axonal polyneuropathy. Muscle Nerve. 1997;20(10):1236–1241. doi: 10.1002/(sici)1097-4598(199710)20:10<1236::aid-mus5>3.0.co;2-d
- Van Den Bergh PYK, Van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force — Second revision. J Peripher Nerv Sys. 2021;26(3):242–268. doi: 10.1111/jns.12455
- Ghoreishi Z, Keshavarz S, Asghari Jafarabadi M, et al. Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer. BMC Cancer. 2018;18(1):958. doi: 10.1186/s12885-018-4869-5
- Jordan B, Jahn F, Sauer S, Jordan K. Prevention and management of chemotherapy-induced polyneuropathy. Breast Care (Basel). 2019;14(2):79–84. doi: 10.1159/000499599
- Timmins HC, Mizrahi D, Li T, et al. Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review. J Cancer Surviv. 2023;17(1):222–236. doi: 10.1007/s11764-021-00988-x
- Morton RF, Sloan JA, Grothey A, et al. A comparison of simple single-item measures and the common toxicity criteria in detecting the onset of oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. JCO. 2005;23(16):8087. doi: 10.1200/jco.2005.23.16_suppl.8087
- Park SB, Kwok JB, Asher R, et al. Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial. Ann Oncol. 2017;28(11):2733–2740. doi: 10.1093/annonc/mdx491
- Burakgazi AZ, Messersmith W, Vaidya D, et al. Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology. 2011;77(10):980–986. doi: 10.1212/WNL.0b013e31822cfc59
- Molassiotis A, Cheng HL, Lopez V, et al. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer. 2019;19(1):132. doi: 10.1186/s12885-019-5302-4
- Холодова Н.Б., Понкратова Ю.А., Синкин М.В. Клинические и электронейромиографические особенности постхимиотерапевтической полинейропатии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2017;117(9):59–66. Kholodova NB, Ponkratova YuA, Sinkin MV. Clinical and electromyography characteristics of chemotherapy-induced polyneuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(9):59–66. doi: 10.17116/jnevro20171179159-66
- Kim SH, Kim W, Kim JH, et al. A Prospective study of chronic oxaliplatin-induced neuropathy in patients with colon cancer: long-term outcomes and predictors of severe oxaliplatin-induced neuropathy. J Clin Neurol. 2018;14(1):81–89. doi: 10.3988/jcn.2018.14.1.81
- Myftiu B, Hundozi Z, Sermaxhaj F, et al. Chemotherapy-Induced Peripheral Neuropathy (CIPN) in patients receiving 4–6 cycles of platinum-based and taxane-based chemotherapy: a prospective, single-center study from Kosovo. Med Sci Monit. 2022;28: e937856. doi: 10.12659/MSM.937856.
- Mansukhani K, Dhonde M, Sreenivasan A, et al. Sural radial amplitude ratio: a study in healthy Indian subjects. Ann Indian Acad Neurol. 2020;23(3):255–260. doi: 10.4103/aian.AIAN_321_20
- Guo Y, Palmer JL, Brown XS, Fu JB. Sural and radial sensory responses in patients with sensory polyneuropathy. Clin Med Rev Case Rep. 2015;2(3):049. doi: 10.23937/2378-3656/1410049
Supplementary files
